Detalhe da pesquisa
1.
Relevance of complement immunity with brain fog in patients with long COVID.
J Infect Chemother
; 30(3): 236-241, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37866620
2.
Examining the association between vaccine reactogenicity and antibody titer dynamics after the third dose of BNT162b2 vaccine using a mixed-effects model.
J Infect Chemother
; 29(1): 39-42, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36168999
3.
Nonrecurrence Rate of Underwater EMR for ≤20-mm Nonampullary Duodenal Adenomas: A Multicenter Prospective Study (D-UEMR Study).
Clin Gastroenterol Hepatol
; 20(5): 1010-1018.e3, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34217879
4.
Aging-related Characteristics of Subclinical Hypothyroidism Detected in General Practice.
Acta Med Okayama
; 76(1): 7-15, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35236993
5.
Comparison of the efficacy and safety between palliative biliary stent placement and duct clearance among elderly patients with choledocholithiasis: a propensity score-matched analysis.
BMC Gastroenterol
; 21(1): 369, 2021 Oct 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34629075
6.
Small intestinal follicular lymphoma induced by methotrexate: a case report.
BMC Gastroenterol
; 21(1): 280, 2021 Jul 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34238226
7.
Association between Equol Production Status and Nonalcoholic Steatohepatitis.
Int J Mol Sci
; 22(21)2021 Nov 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34769332
8.
Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis.
Int J Mol Sci
; 22(13)2021 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34203178
9.
Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis.
Hepatol Res
; 50(7): 840-852, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32346970
10.
Effect of furosemide on muscle cramps in patients with liver cirrhosis.
J Gastroenterol Hepatol
; 35(1): 76-81, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31385352
11.
Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis.
Int J Mol Sci
; 21(15)2020 Aug 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32759852
12.
Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis.
Int J Mol Sci
; 21(6)2020 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32245205
13.
Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis.
Hepatol Res
; 49(3): 284-295, 2019 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-30365236
14.
Identification of clinical risk factors for histological progression of primary biliary cholangitis.
Hepatol Res
; 49(9): 1015-1025, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31021038
15.
Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis.
Hepatol Res
; 49(2): 232-238, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30198141
16.
Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis.
Hepatol Res
; 49(10): 1147-1161, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31177586
17.
Exogenous Administration of Low-Dose Lipopolysaccharide Potentiates Liver Fibrosis in a Choline-Deficient l-Amino-Acid-Defined Diet-Induced Murine Steatohepatitis Model.
Int J Mol Sci
; 20(11)2019 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31163617
18.
Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake.
Int J Cancer
; 142(8): 1712-1722, 2018 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29205334
19.
Treatment of long-segment Barrett's adenocarcinoma by complete circular endoscopic submucosal dissection: a case report.
BMC Gastroenterol
; 18(1): 16, 2018 Jan 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29351773
20.
Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis.
Hepatol Res
; 47(12): 1317-1328, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28029729